MediGene and bluebird bio struck a collaborative deal to develop T cell receptor (TCR) immunotherapies against four targets that could be worth more than $1 billion.
Genentech, a member of the Roche Group, licensed HM95573 from Seoul, South Korea-based Hanmi Pharmaceutical Co. for a deal that could hit $910 million.
Every once in a while it’s refreshing for a healthcare digital strategist or innovation officer to take a close look at how marketing technology is being used outside of pharma.
The world’s largest insulin maker, Novo Nordisk, is cutting 1,000 jobs as a part of a plan to reduce costs as it faces a challenging environment in 2017, especially in the large U.S. market.
Swiss biotech group Actelion Ltd. will investigate an all-oral combination therapy for patients with relapsing multiple sclerosis (RMS), calling it the first study of this approach for treating the neurological disorder.
Medtronic Plc won U.S. approval for an “artificial pancreas” that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day.
Two simple tests that can be done in a doctor’s office may be able to rule in or out a painful hip condition that is usually hard to diagnose without magnetic resonance imaging (MRI), according to a small study.
U.S. Senators Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the Justice Department to investigate whether Mylan NV may have misclassified its EpiPen in order to pay lower rebates to the states.
Boehringer Ingelheim and ViraTherapeutics will jointly develop a next-generation oncolytic virus therapy platform and investigate ViraTherapeutics’ lead candidate.